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Objectives:
1. Identify indications and contraindications for CRRT and compare
CRRT to intermittent dialysis therapy.
2. Discuss the importance of a multidisciplinary team approach to
managing patients on CRRT.
3. Discuss the use of replacement fluids and dialysates in CRRT.
4. Describe pharmacy and nursing management during initiation and
maintenance of CRRT.
5. Discuss potential complications of CRRT.
6. Discuss essential components of nursing and pharmacy care for
patients receiving CRRT.

Introduction
• What is Continuous Renal Replacement Therapy
(CRRT)?
• CRRT was developed in 1980’s to provide
artificial kidney support to patients who could
not tolerate traditional hemodialysis.
• The use of CRRT has increased dramatically in
recent years.

The Multidisciplinary Team
• Usually led by a nephrologist.
• The team should include:
Critical care nurse
Dialysis nurse
Clinical pharmacist
Dietician
Clinical laboratory
Consulting physicians

Continuous vs. Intermittent Renal
Replacement Therapy
• Intermittent therapies are performed every 2-3 days
and last about 3-4 hours.
• During traditional hemodialysis treatment, large
amounts of fluids, electrolytes and toxins are removed.
• Intermittent hemodialysis requires that patients’
protein and fluid intake be limited between treatments.
• CRRT addresses these needs by providing slow,
continuous removal of toxins and fluids continuously
over a 24-hour period.

Continuous vs. Intermittent Renal
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Indications for CRRT
• Any patient who meets criteria for hemodialysis but
cannot tolerate intermittent dialysis due to
hemodynamic instability.
• Includes patients with:
 Fluid overload
 Acute renal failure
 Chronic renal failure
 Life-threatening electrolyte imbalance
 Drug overdose
 Major burns

Contraindications for CRRT
• Advance directives indicating the patient does
not desire dialysis or life-sustaining therapy.
• Patient or family refusal of therapy.
• Inability to establish vascular access.

Principles of Renal Replacement
Therapy
1. Ultrafiltration
2. Convection
3. Adsorption
4. Diffusion

Vascular Access
• Venovenous is by far
the most commonly
used today.
• Common sites include
the jugular, subclavian
and femoral veins.

Fluids Used in CRRT
Dialysate: any fluid used on the opposite
side of the filter from the blood.
• Typical flow rates are 600-1800ml/hr.
• Note: sodium bicarbonate has a low
compatibility with calcium. If both are
added to a bag in sufficient quantities, it
will cause a precipitate and clog the filter!

Fluids Used in CRRT
Replacement Fluids:
• Used to increase the amount of solute that is removed
in CRRT.
• They don’t actually REPLACE anything!
• Typical flow rates are 1000-2000ml/hr.

Total Parenteral Nutrition (TPN):
• Not actually part of CRRT, but is usually given
concurrently.

Anticoagulation and CRRT
Heparin
• Carries the risk of heparin-induced
thrombocytopenia and thrombosis (HITT)
• HITT should be suspected if platelet counts
drop by more than 50% from baseline after
heparin therapy is begun.

Anticoagulation and CRRT
Trisodium Citrate
• Inhibits clotting by binding calcium, a key
cofactor in the clotting cascade.
• Eliminates the risk of HITT, and does not cause
systemic anticoagulation.
• A calcium chloride infusion is administered to
the patient to replace the calcium bound by the
citrate.

Anticoagulation and CRRT
No anticoagulation
• It may be safer to avoid anticoagulation:
“losing the filter is better than losing the
patient!”
• Contraindicated in patients with:






Platelet count <50,000/mm3
INR > 2.0
aPTT > 60 seconds
Active bleed
Severe hepatic dysfunction

Types of CRRT Therapy
Slow Continuous Ultrafiltration (SCUF)
• Uses no dialysate or replacement fluid.

Continuous VenoVenous Hemofiltration (CVVH)
• Uses replacement fluids, but no dialysate.

Continuous VenoVenous HemoDialysis (CVVHD)
• Dialysate is run, but no replacement fluid.
• Very similar to traditional hemodialysis.

Continuous VenoVenous HemoDiaFiltration (CVVHDF)
• Uses both dialysate and replacement fluid.
• Most flexible of all therapies.

Complications of CRRT
• Bleeding
• Hypothermia
• Electrolyte imbalances
• Acid-Base imbalances
• Infection

Appropriate Dosing of Medications
• CRRT therapies clear most renally excreted
drugs as efficiently as patients with normal
renal function.
• Doses do not need to be empirically reduced for
renal dysfunction while CRRT is running.
• Be aware that doses may need to be increased
when CRRT is started, and decreased when
CRRT is discontinued.

Conclusion
• The critical care nurse is responsible for administering
CRRT and assessing the patient’s response to therapy.
• The nurse is also the primary communicator in the
CRRT process.
• The pharmacist is responsible for the compounding of
the various solutions and medications required.
• The pharmacist, as part of the multidisciplinary team,
assists in adjusting the doses and formulas of the
various therapies.

Conclusion
Products provided by pharmacy in the
provisionof CRRT:
• Dialysate
• Replacement fluids
• Anticoagulation (heparin or citrate)
• Calcium chloride (if citrate is used)
• TPN
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